Open AccessClinical utility of target capture‐based panel sequencing in hematological malignancies: A multicenter feasibility study
Author(s) -
Yasuda Takahiko,
Sanada Masashi,
Nishijima Dai,
Kanamori Takashi,
Iijima Yuka,
Hattori Hiroyoshi,
Saito Akiko,
Miyoshi Hiroaki,
Ishikawa Yuichi,
Asou Norio,
Usuki Kensuke,
Hirabayashi Shinsuke,
Kato Motohiro,
Ri Masaki,
Handa Hiroshi,
Ishida Tadao,
Shibayama Hirohiko,
Abe Masahiro,
Iriyama Chisako,
Karube Kennosuke,
Nishikori Momoko,
Ohshima Koichi,
Kataoka Keisuke,
Yoshida Kenichi,
Shiraishi Yuichi,
Goto Hiroaki,
Adachi Souichi,
Kobayashi Ryoji,
Kiyoi Hitoshi,
Miyazaki Yasushi,
Ogawa Seishi,
Kurahashi Hiroki,
Yokoyama Hisayuki,
Manabe Atsushi,
Iida Shinsuke,
Tomita Akihiro,
Horibe Keizo
Publication year - 2020
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.14552
Subject(s) - medicine , multiple myeloma , clinical trial , oncology , lymphoma , myeloid leukemia , acute leukemia , leukemia , cancer
Abstract Although next‐generation sequencing‐based panel testing is well practiced in the field of cancer medicine for the identification of target molecules in solid tumors, the clinical utility and clinical issues surrounding panel testing in hematological malignancies have yet to be fully evaluated. We conducted a multicenter prospective clinical sequencing study to verify the feasibility of a panel test for hematological tumors, including acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, and diffuse large B‐cell lymphoma. Out of 96 eligible patients, 79 patients (82%) showed potentially actionable findings, based on the clinical sequencing assays. We identified that genetic alterations with a strong clinical significance were found at a higher frequency in terms of diagnosis (n = 60; 63%) and prognosis (n = 61; 64%) than in terms of therapy (n = 8; 8%). Three patients who harbored a germline mutation in either DDX41 (n = 2) or BRCA2 (n = 1) were provided with genetic counseling. At 6 mo after sequencing, clinical actions based on the diagnostic (n = 5) or prognostic (n = 3) findings were reported, but no patients were enrolled in a clinical trial or received targeted therapies based on the sequencing results. These results suggest that panel testing for hematological malignancies would be feasible given the availability of useful diagnostic and prognostic information. This study is registered with the UMIN Clinical Trial Registry (UMIN000029879, multiple myeloma; UMIN000031343, adult acute myeloid leukemia; UMIN000033144, diffuse large B‐cell lymphoma; and UMIN000034243, childhood leukemia).